Dual Kaletra/Isentress HIV regimen looks as effective as traditional HAART
This article was originally published in Scrip
Executive Summary
A two-drug HIV treatment regimen consisting of Abbott's protease inhibitor Kaletra (lopinavir 400mg/ritonavir 100mg) and Merck & Co's integrase inhibitor Isentress (raltegravir) has comparable efficacy to a traditional three-drug highly active antiretroviral treatment (HAART) regimen of Kaletra and Gilead Sciences' combined nucleotide/nucleoside reverse transcriptase inhibitor Truvada (emtricitabine 300mg and tenofovir disoproxil fumarate 200mg), preliminary study findings suggest.
You may also be interested in...
P&G to co-promote Somaxon's Silenor in the US
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GSK's shingles vaccine begins Phase III studies
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
Optimer's fidaxomicin filing accepted in EU
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.